Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9336738 | Cancer Treatment Reviews | 2005 | 13 Pages |
Abstract
Despite these encouraging results, a French randomised trial has failed to demonstrate any advantage of HDCT in the first-line treatment of poor-risk GCTs and thus the place of HDCT in routine practice remains uncertain. A number of randomised trials of HDCT are currently ongoing in the United States and Europe to better define the role of HDCT in this disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L. El-Helw, R.E. Coleman,